Market capitalization | $2.81b |
Enterprise Value | $2.48b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 75.57 |
P/S ratio (TTM) P/S ratio | 85.67 |
P/B ratio (TTM) P/B ratio | 3.58 |
Revenue growth (TTM) Revenue growth | 13,669.75% |
Revenue (TTM) Revenue | $32.77m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
12 Analysts have issued a Iovance Biotherapeutics Inc forecast:
12 Analysts have issued a Iovance Biotherapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 33 33 |
13,554%
13,554%
|
|
Gross Profit | -41 -41 |
68%
68%
|
|
EBITDA | -419 -419 |
4%
4%
|
EBIT (Operating Income) EBIT | -459 -459 |
7%
7%
|
Net Profit | -440 -440 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Head office | United States |
CEO | Frederick Vogt |
Employees | 557 |
Founded | 2007 |
Website | www.iovance.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.